Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

LXEO Total Current Liabilities

All obligations due within one year.

Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities falls 54.0% from a year ago

Total current liabilities stood at $14.19M at the end of Q1 FY2026, down 54.0% from a year earlier and down 15.6% from the prior quarter. Over 3 fiscal years it compounded at +5.4% a year.

Context

  • Total current liabilities amounted to 5.7% of total assets at the end of Q1 FY2026, down 18.9 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -54.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.19M-15.6% QoQ
Last fiscal yearDec 2025
$16.81M-26.4% YoY
Year agoMar 2025
$30.82M-54.0% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.0%——
1 year-26.4%——
3-year CAGR+5.4%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
16.81M USD
Year-over-year change
-26.4%
4-year CAGR
+22.6%

Total Current Liabilities vs competitors

How LXEO compares with its peers on the latest reported figures

  • LXEO's Mar 2026 total current liabilities of $14.19M is the 8th highest of the 11 companies compared; the peer median is $31.66M.
  • Its year-over-year change of -54.0% is the 10th highest of 11, against a peer median of -0.1%.
  • Total current liabilities amounts to 5.7% of total assets for LXEO, versus a peer median of 13.4%.
LXEO Competitors Peer median
Total Current Liabilities for LXEO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AMRNAmarin Corporation plcMar 2026$179.64M +10.6%-9.2%27.8%
VNDAVanda Pharmaceuticals Inc.Mar 2026$135.58M +30.5%+16.7%31.3%
DBVTDBV Technologies S.A.Mar 2026$51.8M +28.3%+25.3%19.4%
LRMRLarimar Therapeutics, Inc.Mar 2026$47.76M +115.8%+82.2%22.9%
CAPRCapricor Therapeutics, Inc.Mar 2026$33.64M +50.6%+15.0%10.3%
KYTXKyverna Therapeutics, Inc.Mar 2026$29.67M -10.9%+45.1%11.5%
VYGRVoyager Therapeutics, Inc.Mar 2026$17.45M -56.6%-28.5%8.0%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$14.19M -54.0%+5.4%5.7%
SLNSilence Therapeutics plcMar 2026$10.46M -45.7%-14.7%9.1%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$6.66M -25.6%+8.9%2.5%
MREOMereo BioPharma Group plcMar 2026$6.18M -17.6%-43.9%15.2%
Peer median (excluding LXEO) $31.66M-0.1%+11.9%13.4%

Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents135.86M77.34M121.47M35.01M63M
Short-term Investments00086.5M118.77M
Net Receivables00000
Inventory00000
Other Current Assets696K371K3K4.6M6.63M
Total Current Assets136.68M80.05M124.29M126.12M188.39M
Property, Plant & Equipment (Net)174K13.78M12.26M10.56M8.86M
Goodwill00000
Intangible Assets00000
Long-term Investments0007.01M68.19M
Tax Assets00000
Other Non-current Assets2K7.49M3.25M3.25M3.25M
Total Non-current Assets176K21.26M15.51M20.82M80.3M
Total Assets136.86M97.08M139.81M146.94M268.69M
Account Payables3.06M2.68M3.79M6.42M4.86M
Short-term Debt0002.67M0
Tax Payables528K506K157K00
Deferred Revenue46K0000
Other Current Liabilities961K2.15M3.36M4.66M4.14M
Total Current Liabilities7.45M14.35M17.24M22.85M16.81M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities185.01M185.03M000
Total Non-current Liabilities185.01M195.68M9.03M7.25M5.21M
Total Liabilities192.46M210.03M26.27M30.1M22.02M
Common Stock1.68K03K3K7K
Retained Earnings(56.17M)(115.45M)(181.84M)(280.17M)(380.13M)
Accumulated OCI(185.01M)(185.03M)0(103K)188K
Other Stockholders Equity863185.03M000
Minority Interest00000
Total Equity(55.6M)(112.95M)113.54M116.84M246.67M
Total Debt013.48M11.64M9.92M7.89M
Net Debt(135.86M)(63.85M)(109.83M)(25.09M)(55.11M)

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Intrinsic Alpha fair value

Locked

Current Price

$2.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.